Doug Janzen

Chairman & Chief Executive Officer

Doug Janzen has been involved in the Life Sciences industry for the past 19 years. He is currently the Founder and President of Northview Ventures, an organization which invests in and provides strategic advisory services to a number of technology companies. Mr Janzen was part of the founding group of Aequus Pharmaceuticals. Previously, Mr Janzen was President and CEO of Cardiome Pharma, a NASDAQ listed drug development company that raised over $300 million from investors, and completed over $1 billion in licensing deals during his tenure. In 2010, Cardiome’s lead product, Brinavess, was approved and launched in Europe by Merck. Prior to that, he was an investment banker with Cormark Securities, acting as Managing Director of Life Sciences. Mr Janzen is Past Chair of LifeSciences BC, has served as a Director with Biotech Canada and currently sits as a Director on a number of public and private boards. He is a past winner of Business in Vancouver’s Top 40 Under 40 Award.

Anne Stevens, BSc, MHA

Chief Operating Officer & Director

Ms Stevens has over ten years of progressive experience in the Pharmaceutical, Biotech, and Medical Device industry. Anne is the Co-Founder and Senior Partner of Northview Ventures, an entity which invests in and provides strategic advisory services to a number of life sciences companies. Ms Stevens was part of the founding group of Aequus Pharmaceuticals and previously held the title of VP of Corporate Development. Prior to her involvement with Aequus, Ms Stevens served as the Corporate and External Affairs Analyst for Cardiome Pharma, where she was responsible for strategic planning and value analysis of internal R&D. Ms Stevens’ earlier experience includes 5 years with Bayer HealthCare, where she was responsible for the commercial success and business development of a portfolio of products within several key therapeutic areas.

Fotios Plakogiannis, BSc, MS, PhD


Dr. Plakogiannis served the Arnold & Marie Schwartz College of Pharmacy for over 45 years and for 25 years was the Director of the of the Division of Pharmaceutical Sciences of the College. He was instrumental in establishing the Scientific Graduate Division (MS and Ph.D. program) and was the recipient of the TASA Award for Lifetime Achievement at LIU, Founders Award, etc., among other prestigious awards. Dr. Plakogiannis has authored three books and more than 100 research papers with the majority in the area of Transdermal Delivery. He has mentored more than 200 MS and Ph.D. degrees, served as chair of the Academy of Pharmaceutical Sciences Basic Pharmaceutics Section, and has presented his work in the USA and Europe. Dr. Plakogiannis  has been a visiting Professor in a number of universities, including but not limited to Kentucky University and the University of Arizona. In addition, he has served as a consultant for the Pharmaceutical Industry and has served as an expert witness in a number of cases. 

Chris Clark, BA, PgD, CA


Mr. Clark has over 20 years finance and accounting experience in public practice and in public and private companies, most recently focused in the medical device sector. Previous experience includes financial leadership roles with large automotive and telecom firms in which he developed deep expertise in the development and management of sophisticated financial systems. A highly sought after consultant for biotechnology startups, Mr. Clark accepted the role of Chief Financial Officer at Neovasc Inc. and was instrumental in the initial and ongoing development of Neovasc as a publicly traded company. He received his designation as a Chartered Accountant from the Institute of Chartered Accountants of England and Wales and articled with KPMG before moving to Canada from England in 1998. He has an honors degree in Economics from Swansea University and a post graduate diploma from Keble College, Oxford.

Jason Flowerday, MBA, BSc


Mr. Flowerday has two decades of experience in healthcare management and communications. Mr. Flowerday joined Knight Therapeutics Inc. in 2014 in the roll of Vice President Commercial Operations following the successful sale of his company, Orphan Canada, to Knight. In his role as founder and Chief Commercial Officer of Orphan Canada (formerly GARD Therapeutics), Mr. Flowerday funded and led the company through in-licensing and commercializing of its lead products which dealt with genetic and rare diseases. Prior to founding Orphan Canada, Mr. Flowerday established RxMedia Healthcare Communications, leading the company through a period of sustained growth and expansion. Mr. Flowerday holds a Bachelor of Science (Honours) from the University of Toronto and a Masters of Business Administration from Queen’s University.  

Rodoula Plakogiannis, PharmD, BCPS, CLS, FNLA


Dr. Plakogiannis is an Associate Professor of Pharmacy Practice at the Arnold & Marie Schwartz College of Pharmacy since 2002; and Adjunct Associate Professor at NYU Langone Medical Center since 2011. She received both her Bachelor of Science in Pharmacy and traditional Doctor of Pharmacy degrees from the Arnold & Marie Schwartz College of Pharmacy & Health Sciences. Dr. Plakogiannis completed an ASHP-accredited specialized pharmacy residency in primary care at the Bay Pines Veterans Medical Center in Tampa, Fl. She is a Board Certified Pharmacotherapy Specialist, a Diplomat and Fellow of the Accreditation Council for Clinical Lipidology, and a Board Certified Clinical Lipid Specialist. She serves as one of the Board of Directors for the Northeastern Lipid Association and on the Accreditation Council for Clinical Lipidology 's Board of Governors. She also serves as the Adverse Drug Reactions Section Editor for the Journal of Pharmacy Practice. Dr. Plakogiannis has presented on a national level in addition to local seminars,and has been invited to serve as a consultant at the Aegerion and Amarin Lipid Pharmaceuticals Advisory Board meetings, among others.